Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

Figure 3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

<p>Auranofin increases the overall survival of OVCAR3 CDX mice. <b>A,</b><i>In vivo</i> imaging system spectrum <i>in vivo</i> images of tumor burden. Mice were treated with placebo, cisplatin, auranofin, or both drugs, following the regimen shown. Mice mark...

保存先:

書誌詳細
第一著者:	Robert J. Lake (22408833) (author)
その他の著者:	Parisa Nikeghbal (22408836) (author), Irina V. Lagutina (15133518) (author), Kimberly K. Leslie (22408839) (author), Mara P. Steinkamp (15136266) (author), Hua-Ying Fan (22408842) (author)
出版事項:	2025
主題:	Cancer Therapeutic Research and Development Methods and Technology Combination Chemotherapy Drug Targets Oncoprotein & tumor suppressor drug targets Ovarian Cancer Preclinical Models Organoids Reversal Of Drug Resistance Xenograft Models
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure 1 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure 2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure 4 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure 5 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure 6 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure 7 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S1 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S3 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S4 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S5 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S6 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S7 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Table 1 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Table S1 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer
著者:: Robert J. Lake (22408833)
出版事項: (2025)

Figure S1 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S2 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S3 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S4 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S5 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S6 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S7 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Figure S8 from HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
著者:: Yuanqing Ma (15052437)
出版事項: (2025)

Supplementary Table S1 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S2 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S3 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S4 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S5 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S6 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S7 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S8 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Table S9 from <i>In Vivo</i> Screening Unveils Pervasive RNA-Binding Protein Dependencies in Leukemic Stem Cells and Identifies ELAVL1 as a Therapeutic Target
著者:: Ana Vujovic (15207479)
出版事項: (2025)

Supplementary Figure 1 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Figure 2 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Figure 3 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Figure 4 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Table 1 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Table 2 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Table 3 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)

Supplementary Table 4 from Pharmacologic Inhibition of SIRT1 Limits the Growth of Tumoral and Metastatic Granulosa Cells by Affecting mTOR, Myc, and E2F Pathways
著者:: Victoria Cluzet (21904843)
出版事項: (2025)